
Stuhini Highlights High-Grade Tungsten Potential at Ruby Creek
Meredith Eades, President and CEO of Stuhini, commented: "Tungsten is increasingly recognized as a strategic metal, essential to both industrial applications and national defense. Our review of the Ruby Creek dataset has confirmed a robust and high-grade tungsten system flanking our existing molybdenum deposit — an opportunity that's been largely overlooked until now. As we continue our systematic approach to exploration, these results add a new layer of value to Ruby Creek and reinforce our commitment to advancing critical mineral assets that align with future demand."
Key Highlights
188 rock samples returning >0.1% WO₃, including 40 samples >1% WO₃ and 3 samples >10% WO₃
Tungsten-bearing structures mapped along multiple faults, shears, and veins up to 1.75 metres wide and over 2.9 km in strike
Drill-ready potential supported by historic drill intercepts of:
0.15% WO₃ over 27.43 m (GD17-003B), including 0.76% over 3.05 m
0.14% WO₃ over 18.29 (GD17-007), including 0.63% over 3.05 m
Channel sampling results from Thor Ridge Trend include:
1.35% WO₃ over 1.75 m, including 2.19% WO₃ over 1 m
Associated gold-silver-copper values: up to 9.27 g/t Au, 225 g/t Ag, and 0.30% Cu (2)
Tungsten System Overview
Mapping and sampling at Ruby Creek have outlined multiple tungsten-bearing structures forming a broad halo around the Ruby Creek molybdenum deposit. These mineralized structures are associated with northeast-southwest trending faults, veins, and shear zones that range from 0.1 to 1.75 metres thick and extend for hundreds to thousands of metres along strike. Primary tungsten minerals identified include wolframite and scheelite.
A total of 188 samples returned >0.1% WO₃, , with 40 samples exceeding 1% WO₃ and 3 returning over 10%. These values occur along well-defined trends, suggesting strong structural control and continuity of mineralization.
Multiple tungsten-bearing trends surround the Ruby Creek molybdenum deposit, with samples returning >10% WO₃ along several faults and splays
Rock samples show a defined tungsten enrichment halo surrounding the Ruby Creek Mo deposit, with 188 samples >0.1% WO₃ and 40 samples >1% WO₃.
Target Zones and Historical Work
Stuhini's internal review has outlined seven priority tungsten zones with strike extents from 750 metres to 4.5 kilometres:
In addition, anomalous tungsten in soils (20–500 ppm) suggests further mineralized structures may be present under till and soil cover along strike.
Next Steps
Stuhini plans to follow up with detailed surface mapping and rock sampling to refine targeting across these structures and potentially identify new tungsten-bearing zones. The tungsten system represents a previously underappreciated critical minerals component of the Ruby Creek Project and will be incorporated into future targeting and project advancement plans.
About the Ruby Creek Project
The 29,734-hectare Ruby Creek Project is located approximately 14 km east of Atlin, BC, and is road-accessible. The property hosts the Ruby Creek molybdenum deposit, which contains a measured and indicated pit-constrained resource of 433 million pounds of molybdenum (using US$15/lb Mo and a 0.02% cutoff) and multiple additional mineral occurrences including gold, silver, tungsten, and copper. Stuhini owns 100% of the Ruby Creek Project, subject to a 1% NSR. (1)
Qualified Person
Mr. Nicholas Clive Aspinall, M.Sc., P.Eng., is a consulting geologist to Stuhini Exploration and is a "qualified person" as defined by National Instrument 43-101. Mr. Aspinall has verified the data disclosed in this press release, including the sampling, analytical and test data underlying the technical information, and has approved the technical information contained herein. Conversion to WO3% = W% x 1.2616.
About Stuhini Exploration Ltd
Stuhini is a mineral exploration company focused on exploration and development of precious and base metals properties in western Canada. The Company's portfolio of exploration properties includes the flagship Ruby Creek Property, 16 km east of Atlin, BC; the South Thompson Nickel Project, 35 km northwest of Grand Rapids, Manitoba; the Big Ledge Property, 57 km south of Revelstoke, BC
For further information on Stuhini, visit our website at www.stuhini.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
1 See "Technical Report, Ruby Creek Project, Northern British Columbia, Canada" effective March 10, 2022 and dated April 22, 2022 authored by Steven Ristorcelli, C. P. G., Peter Ronning, P. Eng., Finley Bakker, P. Geo., and John Eggert, P. Eng.
2 See press release dated January 12, 2022
SOURCE Stuhini Exploration Ltd.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Toronto Star
41 minutes ago
- Toronto Star
Titanium Reports Q2 2025 with 16.8% Logistics Revenue Increase; Further Debt Reduction Strengthens Balance Sheet
Consolidated revenue for Q2 2025 grew 3.5% year-over-year, to $119.1 million, driven by strength in the Logistics segment. Logistics revenue increased 16.8% year-over-year, fueled by 19% increase in US volume, highlighting growth of new customers and the scalability of Titanium's asset-light model. Enhanced financial flexibility with $12.4 million in debt reduction, $16.4 million cash on hand. BOLTON, Ontario, Aug. 11, 2025 (GLOBE NEWSWIRE) — Titanium Transportation Group Inc. ('Titanium' or the 'Company') (TSX:TTNM, OTCQX:TTNMF), a leading provider of transportation and logistics services throughout North America, is pleased to report its financial results for the three and six-month period ended June 30, 2025. All amounts are in Canadian currency.


Cision Canada
41 minutes ago
- Cision Canada
AGEDB Technology Cancels Share Consolidation
VANCOUVER, BC, Aug. 11, 2025 /CNW/ - AGEDB Technology Ltd. (" AGEDB" or the " Company") (TSXV: AGET) announces that, further to the Company's news release dated June 10, 2025, the Board of Directors have determined not to proceed on the consolidation of the Company's common shares at this time. About AGEDB Technology Ltd. AGEDB Technology Ltd. (TSXV : AGET) is a leading provider of enterprise database solutions. The company specializes in advanced database technologies, including graph databases and data processing systems, offering robust solutions to clients worldwide. AGEDB Technology Ltd. On behalf of the board of directors, "Young Seung Ko" Director Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. SOURCE AGEDB Technology Ltd.


Globe and Mail
41 minutes ago
- Globe and Mail
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO , Aug. 11, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows: Director For % Withheld % Patricia Andrews 10,498,328 88.83 % 1,320,714 11.17 % Deborah M. Brown 10,115,110 85.58 % 1,703,932 14.42 % Jared Kelly 10,830,605 91.64 % 988,437 8.36 % Angela Holtham 10,175,887 86.10 % 1,643,155 13.90 % James T. Parsons 10,172,958 86.07 % 1,646,084 13.93 % Wayne Pisano 10,148,894 85.87 % 1,670,148 14.13 % Jonathan Rigby 9,508,770 80.45 % 2,310,272 19.55 % Bernd R. Seizinger 10,269,441 86.89 % 1,549,601 13.11 % In addition to the election of all nominees listed as directors in the management information circular, dated June 18 , 2025, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year. For more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: or follow the Company on social media on LinkedIn and on X @ oncolytics. Company Contact Jon Patton Director of IR & Communication jpatton@ Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 mmoyer@ Media Contact for Oncolytics Owen Blaschak LifeSci Communications oblaschak@ Logo - SOURCE Oncolytics Biotech® Inc.